Cardiovascular disease remains the leading cause of death worldwide, claiming more lives each year than all forms of cancer and affecting more than 32% of the world's population (1 death per 40 seconds).
The direct and indirect costs of cardiovascular disease and stroke are about $315 billion and increasing.
Despite recent advances in medical and device therapies, the incidence, hospitalization, and mortality rate for heart failure continue to rise.
Cardiovascular therapies that exist today primarily alleviate the symptoms and do not address the underlying root causes of cardiac diseases.
Cardiovascular disease is a difficult and complicated therapeutic area because the heart is the least regenerative organ in the human body.
In the event of a myocardial infarction, billions of cardiomyocytes die, placing more strain on other regions of the organ to continue to pump and supply blood to the body.
Cardiovascular disease is in the top five indications of cell and gene therapy research, with over 1,500 clinical trials underway, and 50+ cell and gene-therapy based companies developing products for the indication.
As therapeutics near commercialization, a safe and effective delivery approach is top of mind to enable high procedure efficacy.
Of the existing methods, the catheter-based transendocardial approach is the only effective delivery approach.
Viper™ meets the industry’s need for safe, targeted delivery of therapeutic and diagnostic agents, enhancing procedural efficacy and improving patient outcomes.
The Viper™ Catheter is currently limited by United States law to investigational use and is not approved for sale or commercial use at this time.
